Completed PHASE1 INTERVENTIONAL 2-arm NCT03401671

Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of a Single Dose of Lanadelumab Administered Subcutaneously in Healthy Adult Japanese Subjects and Matched Healthy Adult Caucasian Subjects

Sponsor: Shire

Conditions Healthy Volunteers

Interventions Lanadelumab

Updated 10 times since 2018 Last updated: May 13, 2021 Started: Jan 15, 2018 Primary completion: May 30, 2018 Completion: May 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Shire and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Sep 2021 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Jan 2021 — Sep 2021 [monthly]

Completed PHASE1
Aug 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Aug 2019 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cypress, United States